Cinryze Approved To Prevent HAE Attacks
This article was originally published in The Pink Sheet Daily
Executive Summary
Other candidates lined up for acute indication
You may also be interested in...
Shire’s ViroPharma Purchase Aims To Build Rare Disease Giant
Shire is buying ViroPharma at a steep premium to acquire its pipeline assets, notably C1 esterase inhibitor Cinryze, which the London-listed specialty pharma plans to expand internationally, initially to treat hereditary angioedema and later for other rare diseases.
ViroPharma Sets High Pricing For Cinryze, Unveils Promotional Plan
Analyst opinions mixed, ranging from increased sales projections to a prediction of HAE competition driving down the price of the orphan therapeutic.
ViroPharma Sets High Pricing For Cinryze, Unveils Promotional Plan
Analyst opinions mixed, ranging from increased sales projections to a prediction of HAE competition driving down the price of the orphan therapeutic.